Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients
Unknown statusNCT03977012
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
In the present study, we aim to investigate the effect of buprenorphine on neuroinflammation in patients with complex regional pain syndrome, using \[11C\]-(R)-PK11195 PET.
Study details
- Official title
- Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome(CRPS) Patients With Chronic Lower Back Pain: A Pilot Study
- Conditions
- Interventions
- Sponsor
- Seoul National University Hospital
- Start date
- 2019-06-11
- Primary completion
- 2024-04-01
- Sex
- All
- Age range
- from 20 Years to 64 Years
- Results posted
- No results posted in this snapshot
- Countries
- South Korea
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Patients diagnosed with complex regional pain syndrome Type I (Budapest Criteria) and persistent back pain (VAS ≥ 4). 2. Patients who can stop benzodiazepine treatment 2 weeks before study 3. Patients who initially decided to use buprenorphine according to clinical judgment 4. Patients who are able to understand the purpose and procedure of the study Exclusion Criteria: 1. Patients with an impaired cognitive function such as psychosis, dementia, or mental retardation 2. Patients with neurologic disease, cerebrovascular disease, history of brain tumor, history of severe head trauma, history of convulsive disease 3. Patients with cardiovascular disease, liver, respiratory or renal dysfunction 4. Patients with biliary disease 5. Patients who could not undergo the PET/magnetic resonance imaging (MRI) process. 6. Patients who have a risk of suicide or show aggressive behavior 7. Patients who have drug dependence (DSM-IV criteria) or history (past 6 months or older) 8. Employees of researchers or clinical research institutes 9. Patients with hypersensitivity or contraindication to buprenorphine
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03977012